<?xml version="1.0" encoding="UTF-8"?>
<p>Yet unconfirmed studies (
 <xref rid="cytoa24047-bib-0044" ref-type="ref">44</xref>, 
 <xref rid="cytoa24047-bib-0045" ref-type="ref">45</xref>) performed early this year reported isolation of various SARS‐CoV‐2 strains from patients with mutations in the RBD. Some of these mutations apparently have increased RBD‐binding affinities. Furthermore, mutated strains seem to be globally unevenly distributed with focuses in distinct global regions. New studies show that all recovered SARS‐CoV‐2 patients (
 <italic>n</italic> = 29) presented IgG/IgM response to spike protein S1 and the titer of S1 specific IgG increases with age (
 <xref rid="cytoa24047-bib-0046" ref-type="ref">46</xref>, 
 <xref rid="cytoa24047-bib-0047" ref-type="ref">47</xref>). Some authors also speculated on the possibility that ADE was induced by SARS‐CoV‐2 in SARS‐CoV convalescent individuals (
 <xref rid="cytoa24047-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="cytoa24047-bib-0028" ref-type="ref">28</xref>), although this view is not unanimously accepted (
 <xref rid="cytoa24047-bib-0029" ref-type="ref">29</xref>), and antisera as well as monoclonal NAbs isolated from eight SARS‐CoV‐2 patients did not bind to SARS‐CoV or MERS‐CoV RBD (
 <xref rid="cytoa24047-bib-0047" ref-type="ref">47</xref>).
</p>
